Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

PRES	CRIB	ER	PATIENT:	
Name:				
Ward:			NHI:	
Enter	al li	quic	l peptide formula	
INITIA				
Prere	quisi	ies (tick boxes where appropriate)	
	and	C	Patient has impaired gastrointestinal function and either cannot tolerate polymeric feeds, or polymeric feeds are unsuitable	
		or	O Severe malabsorption	
		or	O Short bowel syndrome	
		or	O Intractable diarrhoea	
		or	O Biliary atresia	
		or	O Cholestatic liver diseases causing malabsorption	
		or	O Cystic fibrosis	
		or	O Proven fat malabsorption	
		or	O Severe intestinal motility disorders causing significant malabsorption	
		or	O Intestinal failure	
			O The patient is currently receiving funded amino acid formula	
			The patient is to be trialled on, or transitioned to, an enteral liquid peptide formula	
	and			
		or	A semi-elemental or partially hydrolysed powdered feed has been reasonably trialled and considered unsuitable	
		<u> </u>	O For step down from intravenous nutrition	
Note:	A rea	ason	able trial is defined as a 2-4 week trial.	
CONT				
Prere	quisi	tes (tick boxes where appropriate)	
An assessment as to whether the patient can be transitioned to a cows milk protein or soy infant formula or extensively hydrolysed formula has been undertaken				
	and (The outcome of the assessment is that the patient continues to require an enteral liquid peptide formula	

I confirm that the above details are correct:	
Signed:	Date: